Can Cui, Ph.D. J.D.

Dr. Can Cui focuses his practice on technology transactions, investments and intellectual property (IP) protection in the life sciences and med-tech industries, with a particular emphasis on cross-border deals involving Asia. His work encompasses technology licensing and acquisition, collaboration and strategic partnerships, joint ventures, and various forms of investment.

Can frequently represents life sciences and med-tech companies, from startups to multinational corporations, in worldwide and U.S.-China life sciences licensing and collaboration transactions, from target or drug discovery phase to clinical stage and beyond. His representation covers the entire value chain, and includes contract research, manufacture and supply, clinical trials, commercialization and distribution arrangements.

In the realm of private equity and venture capital, he regularly conducts IP due diligence and negotiates investment documentation for institutional and individual investors, and emerging and established life sciences and med-tech companies. Additionally, Can advises clients on IP aspects of mergers and acquisitions.

With his deep understanding of both China’s and U.S.’s regulatory landscapes, in connection with his cross- border transactional practice, Can provides guidance on China and U.S. IP laws, technology import and export regulations, cross-border investment restrictions, and data privacy laws and regulations. His wide-ranging experience in corporate matters, patent prosecution, and IP dispute resolution, combined with his scientific education, allows him to offer advice to life sciences and med-tech companies on a variety of legal issues they may face.

In his venture capital and emerging technology practice, Dr. Cui serves as an advisor to life sciences startup companies and organizations across the United States and in China. For example, he works with life sciences startup companies in H7 BioCapital’s Accelerator Program 1:1 to help them determine how best they can fit into the market and develop from ideas to Series A. He is an advisor to the Boston Capital Investment Club and the Clinical Translational Catalyst program at Hong Kong Science & Technology Parks Corporation. He is also an advisor and a core member of the Life Sciences Advisory Council to the SWAN Impact Network, one of the most prominent impact angel networks in the United States. In addition, Dr. Cui is the Vice Chairman of the Professional Committee on Transactions and Mergers and Acquisitions of the Chinese Biopharmaceutical Industrial Chain Innovation and Transformation Alliance.

Besides his private practice, Dr. Cui is also an active contributor to the academia. While working in Hong Kong as a registered foreign lawyer, he served as an adjunct faculty member at The Chinese University of Hong Kong Faculty of Law for three years, where he taught the course on Principles of Intellectual Property and established the course on Chinese IP Law. He is a frequent guest lecturer and panelist at top universities and law schools in the United States and in China on IP protection and technology transactions.

Before and while attending law school, Can worked as a U.S. patent agent, focusing on patent prosecution in the life sciences and pharmaceutical industries.

Concentrations

•Life sciences and med-tech licensing, collaboration and strategic partnerships
•International joint ventures
•Intellectual property protection and strategic counseling
•Asia and China practice
•Cross-border technology transactions and investments

Recognition & Leadership

Awards & Accolades

•Listed, The Best Lawyers in America, 'Ones to Watch,' Technology Law, 2024
•Listed, The Legal 500 United States, Life Sciences, 2022-2023